Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 12, 2026

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation ↗

Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile ↗

January 28, 2026

Via Chartmill

January 06, 2026

Via Chartmill

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

January 29, 2026

Alnylam could have a catalyst on the way.

Should You Buy Alnylam Pharmaceuticals Before Feb. 12? ↗

January 28, 2026

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Topics Earnings

January 11, 2026

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

Via PredictStreet

Topics Economy Intellectual Property Stocks

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 17, 2025

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 11, 2025

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A Prime GARP Candidate for Affordable Growth ↗

December 10, 2025

Alnylam Pharmaceuticals exemplifies the GARP strategy, offering strong growth and profitability at a reasonable price compared to biotech peers.

Via Chartmill

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Alnylam Pharmaceuticals Announces Changes to Board of Directors

December 03, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Via Investor's Business Daily

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Via Benzinga

Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money ↗

November 11, 2025

No investment is a slam dunk to double your money. But these great stocks appear to have what it takes.

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

Topics Intellectual Property

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 08, 2025

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

November 07, 2025

Via Benzinga

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Via Investor's Business Daily

Topics Death

What Does the Market Think About Alnylam Pharmaceuticals Inc? ↗

November 06, 2025

Via Benzinga

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 04, 2025

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

November 02, 2025

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday? ↗

October 30, 2025

Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion.

Via Benzinga

Topics Law Enforcement

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings ↗

October 30, 2025

Alnylam's Q3 2025 earnings crushed estimates with a $2.90 EPS and 149% revenue growth, driven by AMVUTTRA, despite a pre-market stock dip.

Via Chartmill

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 30, 2025